ArticleBMJ oncologyPublished
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison
Regional connection
Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source
- Institution
- Bristol Myers Squibb
- County
- Mercer County
Publication record
- Type
- Article
- Venue
- BMJ oncology
- Published
- Topic
- Clinical care
- Subject terms
- Immunotherapy; Skin Cancer (Malignant Melanoma)
- PubMed ID
- 41971757
- PubMed Central ID
- PMC13064201
- Open access
- Yes, open
- Added to directory
- Source checked